1 / 41

Neurological Complications following SCI William McKinley MD Director, SCI Rehabilitation Medicine Associate Professor

Neurological Complications following SCI William McKinley MD Director, SCI Rehabilitation Medicine Associate Professor PM&R VCU / MCV. Overview of Spinal Cord Function / Injury. Movement (Weakness) Sensation (Sensory loss, Pain) Muscle tone (Spasticity) Bladder/bowel (Neurogenic B/B)

Download Presentation

Neurological Complications following SCI William McKinley MD Director, SCI Rehabilitation Medicine Associate Professor

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Neurological Complications following SCIWilliam McKinley MDDirector, SCI Rehabilitation Medicine Associate Professor PM&RVCU / MCV

  2. Overview of Spinal Cord Function / Injury • Movement (Weakness) • Sensation (Sensory loss, Pain) • Muscle tone (Spasticity) • Bladder/bowel (Neurogenic B/B) • Sexuality (Sexual dysfunction)

  3. Neurological Complications Following SCI • Syringomyelia • Pain • Spasticity

  4. Syringomyelia • Syrinx = fluid filled cavity (cyst) within the spinal cord • Syringomyelia = neurological symptoms due to syrinx • incidence - 3-10% • etiology - trauma, tumor, congenital • area of tissue damage / inflammation • can expand, elongate, cause pressure

  5. Syringomyelia: symptoms • Pain (radicular) • Sensory loss • weakness • Spasticity • Hyperhydrosis • Bladder / bowel

  6. Syringomyelia Diagnosis / Treatment • Dx: • clinical findings / suspicion, physical exam • MRI (CT/myelogram, U/S) • Rx • surgical shunt / drainage to “low” pressure points • syrigopleural, syringoperitoneal) • pain management

  7. SCI PAIN • Challenging issue • Physiologically & psychologically • Incidence 15 - 85 % • Etiology • Spinal cord pain • Radicular • Muscuoskelletal

  8. Factors associated with SCI Pain • Level of Injury (LOI) • Complete vs Incomplete • Time since injury • Type of injury (GSW, trauma) • Psychological factors

  9. Classification of SCI PAIN • Central Pain • Central Pain - below LOI, symmetrical (burning, tingling) • Radicular Pain • At the LOI, asymmetrical (aching, stabbing) • Musculoskelletal Pain • localized MS structures (aching, tender)

  10. Mechanism of Neurogenic SCI Pain • largely unknown • Irritation / abnormal firing of damaged nerve axons or roots • Loss of descending inhibition

  11. management of SCI Pain • Pharmacological - neuropathic pain meds • Surgery • Adjunctive treatments • Psychological Rx

  12. Neuropathic meds • Anticonvulsants (nerve membrane stabilization) • Neurontin, Tegretol, Dilantin • Antidepressants (increase Seritonin levels) • Elavil, Trazadone • Others : Mexiletine • Epidural agents • Morphine, Clonidine, baclofen

  13. Non-pharmacologic Rx • Spinal cord stimulation • ? effectiveness • Surface TENS • best with radicular pain incomplete injuries • Surgery • Dorsal Root Entry Zone (DREZ)

  14. Spasticity • Definition: “Abnormal, velocity-dependent increase in resistance to passive movement of peripheral joints due to increased muscle activity”

  15. Spasticity: Etiology (Diagnosis) • Spinal Cord Injury • Traumatic Brain Injury • Stroke • Multiple Sclerosis • Cerebral Palsy

  16. Pathophysiology • Intrinsic hyperexcitability of alpha motor neurons within the spinal cord secondary to damage to descending pathways • cortico, vestibulo, reticulospinal • CNS modification • neuronal sprouting • denervation hypersensitivity

  17. NEGATIVE SX’s Weakness Function Sleep Pain Skin, hygiene Social, Sexuality contractures USEFUL SX’s Stability Function Circulation Muscle “bulk” Symptoms of Spasticity

  18. Spasticity: Treatment Decisions • Is Spasticity: • Preventing function?, Painful? • A result of underlying treatable stimulus • A set-up for further complications? • What Rx has been tried? • Limitations and SE’s of Rx… • Therapeutic goals

  19. Goals of Therapy • Ease function (ambulation, ADL) • Decrease Pain, contracture • Facilitate ROM, hygiene

  20. Ashworth Scale 1= no increased tone 2= slight “catch” in ROM 3= moderate tone, easy ROM 4= marked tone, difficult ROM 5= Rigid in flexion or extension Spasm Frequency Scale 0= none 1= mild 2= infrequent 3=> 1 per hour 4= > 10 per hour Spasticity Scales

  21. Rehab Evaluation (con’t) • Gait patterns • Transfer abilities • Resting positioning • Balance • Endurance

  22. Management Options • Physical interventions • systemic medications • chemical denervation • Intrathecal agents • orthopedic interventions • neurosurgical interventions

  23. Rehabilitation Interventions • Positioning (bed, wheelchair) • Modalities • heat (relaxation) • cold (inhibition) • Therapeutic Exercise • inhibitory to spastic muscles • facilatory to opposing muscles • Orthotics

  24. Non-Conservative Treatment Options • Oral Medications • Injections (Phenol , Botox) • ITB (Intra-Thecal Baclofen) • Surgical (nerve, root, SC) • Spinal Cord Stimulator

  25. Oral Antispasticity Medications • Baclofen • Dantrium • Diazepam • Clonidine • Tizanidine • (limitations: non-selective, side effects)

  26. Baclofen (Lioresal) • GABA-B analogue; binds to receptors • inhibits release of excitatory neurotransmitters (spasticity control) • Ca++ (pre-synaptic inhibition) • K+ (post-synaptic inhibition) • may also decrease release of substance P (pain control)

  27. Dantrium • Inhibits Ca++ release at muscle level • Preferred : TBI, CVA, CP • SE’s - weakness, GI • Hepatotoxicity (<1%)

  28. Diazepam • GABA “potentiation” • Usage : SCI, MS • SE’s - CNS depression, dependence,

  29. Clonidine • Alpha-2 receptor blockage • Usage : SCI • Max dose - .4mg/d (oral & patch) • SE’s - OH, syncope, drowsiness

  30. Tizanidine (Zanaflex) • 1996 - Approved for SCI, MS, CVA • Alpha-2 agonist (pre-synaptic inhibition) • 1/10 potency of Clonidine In lowering BP • Dose: T1/2: 2-5hr, begin 4 mg qhs (max 36 mg) • SE’s - Sedation, nausea, LFT’s

  31. Chemical Neurolysis • Phenol 5-7%- Motor Point/Nerve block • Non-selective destruction of axons/myelin • Inds: Local (not general) spasticity • Duration: 3-6 months • SE’s - dysesthetic pain

  32. Botulinum Toxin • 1989 FDA approved for strabismus & blepherospasm • Botox-A inhibits Ach Release at NMJ • Dose: 300-400u total (50-200/muscle) • Onset: 2-4 hours, Peak : 2-4 weeks • Duration: 3-6 months • ? Immunoresistance w/repeated inj’s

  33. Spasticity: Surgical Management • Rhizotomy (posterior) • Cordotomy • Tendon Release • (limitations: invasive, bowel/bladder changes, irreversible, effectiveness varies)

  34. Intrathecal Baclofen and Spasticity • Intrathecal delivery of baclofen via an inplantable pump is a safe and effective therapy for the management of spasticity !

  35. Intrathecal Baclofen • Indicated for patients unresponsive to oral meds or with SE’s • Delivered directly to intrathecal space affording much higher drug concentration • Implantable system allows non-invasive monitoring & adjustments

  36. ITB: Successful Outcomes • Study results since 1984 demonstrate reduction of Ashworth spasticity scores and spasm scales • Other results include improvements in: • pain • bladder function • chronic drug side effects • quality of life for patient & caregiver

  37. ITB • 1992 - FDA Approved ITB for spinal Spasticity • 1996 - FDA Approved for Cerebral Etiologies (BI and CP)

  38. ITB: Pharmacokinetics • Baclofen: GABA-b agonist; inhibits neuronal firing • ITB (Lioresal) • preservative-free; stable for 90 days • half-life 1.5 hours • typical dose: 1/100 of oral dose • average daily dose: 300-800ug • lumbar/cervical ratio 4:1

  39. Decision to Treat w/ ITB • Have oral antispasticity meds truly failed? • Are their SE’s too great? • Can a single definitive surgical procedure accomplish similar goals? • Is precise control necessary for functional gains? • Does gain in function / comfort justify invasive procedure & maintenance?

  40. Other Considerations ITB • Test dosing / trial dose via intrathecal lumbar puncture • Pump re-programming via radio-telemetry and computer • Maintenance follow-up: Q 4-12 weeks

  41. THE END

More Related